via University of Pittsburgh School of Medicine
Today in Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19.
These special llama antibodies, called “nanobodies,” are much smaller than human antibodies and many times more effective at neutralizing the SARS-CoV-2 virus. They’re also much more stable.
“Nature is our best inventor,” said senior author Yi Shi, Ph.D., assistant professor of cell biology at Pitt. “The technology we developed surveys SARS-CoV-2 neutralizing nanobodies at an unprecedented scale, which allowed us to quickly discover thousands of nanobodies with unrivaled affinity and specificity.”
To generate these nanobodies, Shi turned to a black llama named Wally—who resembles and therefore shares his moniker with Shi’s black Labrador.
Shi and colleagues immunized the llama with a piece of the SARS-CoV-2 spike protein and, after about two months, the animal’s immune system produced mature nanobodies against the virus.
Using a mass spectrometry-based technique that Shi has been perfecting for the past three years, lead author Yufei Xiang, a research assistant in Shi’s lab, identified the nanobodies in Wally’s blood that bind to SARS-CoV-2 most strongly.
Then, with the help of Pitt’s Center for Vaccine Research (CVR), the scientists exposed their nanobodies to live SARS-CoV-2 virus and found that just a fraction of a nanogram could neutralize enough virus to spare a million cells from being infected.
These nanobodies represent some of the most effective therapeutic antibody candidates for SARS-CoV-2, hundreds to thousands of times more effective than other llama nanobodies discovered through the same phage display methods used for decades to fish for human monoclonal antibodies.
Shi’s nanobodies can sit at room temperature for six weeks and tolerate being fashioned into an inhalable mist to deliver antiviral therapy directly into the lungs where they’re most needed. Since SARS-CoV-2 is a respiratory virus, the nanobodies could find and latch onto it in the respiratory system, before it even has a chance to do damage.
In contrast, traditional SARS-CoV-2 antibodies require an IV, which dilutes the product throughout the body, necessitating a much larger dose and costing patients and insurers around $100,000 per treatment course.
“Nanobodies could potentially cost much less,” said Shi. “They’re ideal for addressing the urgency and magnitude of the current crisis.”
In collaboration with Cheng Zhang, Ph.D., at Pitt, and Dina Schneidman-Duhovny, Ph.D., at the Hebrew University of Jerusalem, the team found that their nanobodies use a variety of mechanisms to block SARS-CoV-2 infection. This makes nanobodies ripe for bioengineering. For instance, nanobodies that bind to different regions on the SARS-CoV-2 virus can be linked together, like a Swiss army knife, in case one part of the virus mutates and becomes drug-resistant.
“As a virologist, it’s incredible to see how harnessing the quirkiness of llama antibody generation can be translated into the creation of a potent nanoweapon against clinical isolates of SARS-CoV-2,” said study coauthor and CVR Director Paul Duprex, Ph.D.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Llama nanobodies
- Why Llama 3 is changing everything in the world of AI
And now, Meta’s Llama LLM (large language model) is becoming an increasingly important player in the game, especially with its open-source nature. Meta recently made a big splash with the launch ...
- Llama 3, the powerhouse behind Meta AI: All you need to know about it
The training data for Llama 3 consists of over 15 trillion tokens, sourced from publicly available data, making it seven times larger than the dataset used for Llama 2. Meta is stepping up its ...
- Zuckerberg says Meta's Llama 3 is really good but no chatbot is sophisticated enough to be an 'existential' threat — yet
Meta launched the latest iteration of its AI chatbot on Thursday with Llama 3, and CEO Mark Zuckerberg says it's supposed to be really good. The new model boasts "state-of-the-art" performance on ...
- How Meta's Llama 3 will be integrated into its AI assistant
Meta is upping the ante in the artificial intelligence race with the launch of two Llama 3 models and a promise to make Meta AI readily available across all its platforms. The tech giant on ...
- Meta releases Llama 3, claims it's among the best open models available
Image Credits: Meta Llama 3 70B beats Gemini 1.5 Pro on MMLU, HumanEval and GSM-8K, and -- while it doesn't rival Anthropic's most performant model, Claude 3 Opus -- Llama 3 70B scores better than ...
Go deeper with Google Headlines on:
Llama nanobodies
[google_news title=”” keyword=”llama nanobodies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Inhalable therapeutics to prevent and treat COVID-19
- Study reveals how COVID-19 vaccines prevent severe disease
A study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
- An effective treatment for COVID-19 is underused
By Nicholas Van Sickles University of Kentucky A safe and effective medication designed to prevent mild-to-moderate COVID-19 infections from becoming more dangerous has been available for almost two ...
- Can Neosporin Protect You From Getting COVID-19?
On its website, the maker of Neosporin says that the product has not "been tested or formulated to prevent against COVID-19 or any other virus," and also note that they do not advise putting the ...
- Cidara Therapeutics To Sell Candidiasis Treatment, Re-acquire Flu Asset
Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner ... an immunotherapy being developed to prevent all strains of the flu, from Johnson & Johnson's Janssen ...
- Gilead’s Veklury receives NICE recommendation to treat COVID-19 in vulnerable adults and children
Gilead Sciences has announced that the National Institute for Health and Care Excellence (NICE) has recommended Veklury (remdesivir) to treat COVID-19 in vulnerable adults and children. The new final ...
Go deeper with Google Headlines on:
Inhalable therapeutics to prevent and treat COVID-19
[google_news title=”” keyword=”inhalable therapeutics to prevent and treat COVID-19″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]